Chronic Myeloid Leukemia (CML)
Publications
Reviewed / Updated: February 2012
2009
- Wright MP, Shepherd JD, Barnett MJ, Nantel SH, Sutherland HJ, Toze CL, Hogge DE, Nevill TJ, Song KW, Abou-Mourad YR, Narayanan S, Power MM, Smith CA, Forrest DL. Response to Tyrosine Kinase Inhibitor Therapy in Patients with Chronic Myeloid Leukemia Relapsing in Chronic and Advanced Phase Following Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant, Epub ahead of print, Dec 2009.
Wright 2009 Response to Tyrosine Kinase Inhibitor Therapy - Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J, Cervantes F, Deininger M, Gratwohl A, Guilhot F, Hochhaus A, Horowitz M, Hughes T, Kantarjian H, Larson R, Radich J, Simonsson B, Silver RT, Goldman J, Hehlmann R; European LeukemiaNet. Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet. J Clin Oncol 27(35): 6041-6051, 2009.
Baccarani 2009 CML An update of concepts - Forrest D, Trainor S, Brinkman R, Barnett M, Hogge D, Nevill T, Shepherd J, Nantel S, Toze C, Sutherland H, Song K, Lavoie J, Power M, Abou-Mourad Y, Smith C. Cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia are correlated with Sokal risk scores and duration of therapy but not trough imatinib plasma levels. Leukemia Research 33: 271-275, 2009.
Forrest 2009 Cytogenetic and molecular reponses to standard-dose imatinib
2008
- Jiang X, Zhao Y, Forrest D, Smith C, Eaves A & Eaves C. Stem Cell Biomarkers in Chronic Myeloid Leukemia. Disease Markers 24: 201-216, 2008.
Jiang 2008 Stem cell biomarkers in CML - Forrest DL, Jiang X, Eaves CJ, Smith CA. An Approach to the Management of Chronic Myeloid Leukemia in British Columbia. Current Oncology 15(2): 90-97, 2008.
Forrest 2008 An approach to the management of CML in BC
Prior to 2008
- Laneuville PJ, Barnett MJ, Belanger R, Couban S, Forrest DL, Roy D-C, Lipton JH. Recommendations of the Canadian Consensus Group on the Management of Chronic Myeloid Leukemia (CCGM-CML). Curr On 13: 1-20, 2006.
Laneuville 2006 Recommendations of the Canadian Consensus Group on the Management of CML - Lin Y, Bruyere MJ, Horsman DE, Pantzar T, Barnett MJ, Hogge DE, Nevill TJ, Nantel SH, Sutherland HJ, Toze CL, Shepherd JD, Lavoie JC, Song KW, Smith CA, Forrest DL. Philadelphia-negative clonal hematopoiesis following imatinib therapy in patients with chronic myeloid leukemia: a report of nine cases and analysis of predictive factors. Cancer Genet Cytogenet 170: 16-23, 2006.
Bruyere 2006 Philadelphia-negative clonal hematopoiesis following imatinib therapy
| The information contained in these guidelines is a statement of consensus of Leukemia/BMT Program of BC professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient’s care or treatment. Use of these guidelines and documents is at your own risk and is subject to the Leukemia/BMT Program of BC’s terms of use available at Terms of Use. |